Farquhar MG , et al.. The Heymann nephritis antigenic complex: Megalin (gp330) and RAP. J Am Soc Nephrol 1995; 6:35−47. https://www.researchgate.net/publication/15620187_The_Heymann_Nephritis_Antigenic_Complex_Megalin_gp330_and_RAP1

• PubMed
Farquhar MG , . The Heymann nephritis antigenic complex: Megalin (gp330) and RAP. J Am Soc Nephrol 1995; 6:35−47. https://www.researchgate.net/publication/15620187_The_Heymann_Nephritis_Antigenic_Complex_Megalin_gp330_and_RAP1 )| false
• Search Google Scholar
• Export Citation

Beck LH Jr , et al.. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361:11−21. doi: 10.1056/NEJMoa0810457

• PubMed
Beck LH Jr , . M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361:11−21. doi: 10.1056/NEJMoa0810457 )| false
• Search Google Scholar
• Export Citation

Tomas NM , et al.. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014; 371:2277−2287. doi: 10.1056/NEJMoa1409354

• PubMed
Tomas NM , . Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014; 371:2277−2287. doi: 10.1056/NEJMoa1409354 )| false
• Search Google Scholar
• Export Citation

Sethi S . New ‘antigens’ in membranous nephropathy. J Am Soc Nephrol 2021; 32:268−278. doi: 10.1681/ASN.2020071082

• PubMed
Sethi S . New ‘antigens’ in membranous nephropathy. J Am Soc Nephrol 2021; 32:268−278. doi: 10.1681/ASN.2020071082 )| false
• Search Google Scholar
• Export Citation

A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative study of the adult idiopathic nephrotic syndrome. N Engl J Med 1979; 301:1301−1306. doi: 10.1056/NEJM197912133012401

• PubMed
A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative study of the adult idiopathic nephrotic syndrome. N Engl J Med 1979; 301:1301−1306. doi: 10.1056/NEJM197912133012401 )| false
• Search Google Scholar
• Export Citation

Ponticelli C , et al.. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1984; 310:946−950. doi: 10.1056/NEJM198404123101503

• PubMed
Ponticelli C , . Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1984; 310:946−950. doi: 10.1056/NEJM198404123101503 )| false
• Search Google Scholar
• Export Citation

Ponticelli C , et al.. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9:444−450. https://loyolamedicine.org/sites/default/files/gme/nephrology/pdfs/jasn_1998_treatment_of_mn.pdf

• PubMed
Ponticelli C , . A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9:444−450. https://loyolamedicine.org/sites/default/files/gme/nephrology/pdfs/jasn_1998_treatment_of_mn.pdf )| false
• Search Google Scholar
• Export Citation

Qin H-Z , et al.. Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients. BMC Nephrol 2017; 18:2. doi: 10.1186/s12882-016-0427-z

• PubMed
Qin H-Z , . Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients. BMC Nephrol 2017; 18:2. doi: 10.1186/s12882-016-0427-z )| false
• Search Google Scholar
• Export Citation

Rostoker G , et al.. Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron 1993; 63:335–341. doi: 10.1159/000187219

• PubMed
Rostoker G , . Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron 1993; 63:335–341. doi: 10.1159/000187219 )| false
• Search Google Scholar
• Export Citation

Praga M , et al.. Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int 2007; 71:924–930. doi: 10.1038/sj.ki.5002215

• PubMed
Praga M , . Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int 2007; 71:924–930. doi: 10.1038/sj.ki.5002215 )| false
• Search Google Scholar
• Export Citation

Ramachandran R , et al.. Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide. Kidney Int Rep 2017; 2:610−616. doi: 10.1016/j.ekir.2017.02.004

• PubMed
Ramachandran R , . Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide. Kidney Int Rep 2017; 2:610−616. doi: 10.1016/j.ekir.2017.02.004 )| false
• Search Google Scholar
• Export Citation

Dahan K , et al.. Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up. J Am Soc Nephrol 2017; 28:348−358. doi: 10.1681/ASN.2016040449

• PubMed
Dahan K , . Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up. J Am Soc Nephrol 2017; 28:348−358. doi: 10.1681/ASN.2016040449 )| false
• Search Google Scholar
• Export Citation

Fervenza FC , et al.. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381:36−46. doi: 10.1056/NEJMoa1814427

• PubMed
Fervenza FC , . Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381:36−46. doi: 10.1056/NEJMoa1814427 )| false
• Search Google Scholar
• Export Citation

Fernández-Juárez G , et al.. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int [published online ahead of print November 7, 2020]. doi: 10.1016/j.kint.2020.10.014; https://www.sciencedirect.com/science/article/pii/S0085253820312515

• PubMed
Fernández-Juárez G , . The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int [published online ahead of print November 7, 2020]. doi: 10.1016/j.kint.2020.10.014; https://www.sciencedirect.com/science/article/pii/S0085253820312515 )| false
• Search Google Scholar
• Export Citation

Scolari F , et al.. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: The RI-CYCLO randomized trial. J Am Soc Nephrol [published online ahead of print March 2021]. doi: https://doi.org/10.1681/ASN.2020071091; https://jasn.asnjournals.org/content/early/2021/02/27/ASN.2020071091

• PubMed
Scolari F , . Rituximab or cyclophosphamide in the treatment of membranous nephropathy: The RI-CYCLO randomized trial. J Am Soc Nephrol [published online ahead of print March 2021]. doi: https://doi.org/10.1681/ASN.2020071091; https://jasn.asnjournals.org/content/early/2021/02/27/ASN.2020071091 )| false
• Search Google Scholar
• Export Citation

KDIGO Clinical Practice Guideline on Glomerular Diseases (Kidney Disease, Improving Global Outcomes [KDIGO]). June 2020. Accessed February 25, 2020. https://kdigo.org/wp-content/uploads/2017/02/KDIGO-GN-GL-Public-Review-Draft_1-June-2020.pdf

• PubMed
KDIGO Clinical Practice Guideline on Glomerular Diseases (Kidney Disease, Improving Global Outcomes [KDIGO]). June 2020. Accessed February 25, 2020. https://kdigo.org/wp-content/uploads/2017/02/KDIGO-GN-GL-Public-Review-Draft_1-June-2020.pdf )| false
• Search Google Scholar
• Export Citation

van de Logt A-E , et al.. Synthetic ACTH in high risk patients with idiopathic membranous nephropathy: A prospective, open label cohort study. PLoS One 2015; 10:e0142033. doi: 10.1371/journal.pone.0142033

• PubMed
van de Logt A-E , . Synthetic ACTH in high risk patients with idiopathic membranous nephropathy: A prospective, open label cohort study. PLoS One 2015; 10:e0142033. doi: 10.1371/journal.pone.0142033 )| false
• Search Google Scholar
• Export Citation

Barrett C , et al.. Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy. Nephrol Dial Transplant 2020; 35:599–606. doi: 10.1093/ndt/gfz086

• PubMed
Barrett C , . Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy. Nephrol Dial Transplant 2020; 35:599–606. doi: 10.1093/ndt/gfz086 )| false
• Search Google Scholar
• Export Citation

Podestà MA , et al.. Accelerating the depletion of circulating anti-phospholipase A2 receptor antibodies in patients with severe membranous nephropathy: Preliminary findings with double filtration plasmapheresis and ofatumumab. Nephron 2020; 144:30−35. doi: 10.1159/000501858

• PubMed
Podestà MA , . Accelerating the depletion of circulating anti-phospholipase A2 receptor antibodies in patients with severe membranous nephropathy: Preliminary findings with double filtration plasmapheresis and ofatumumab. Nephron 2020; 144:30−35. doi: 10.1159/000501858 )| false
• Search Google Scholar
• Export Citation

Bontscho J , et al.. Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J Am Soc Nephrol 2011; 22:336–348. doi: 10.1681/ASN.2010010034

• PubMed
Bontscho J , . Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J Am Soc Nephrol 2011; 22:336–348. doi: 10.1681/ASN.2010010034 )| false
• Search Google Scholar
• Export Citation

Appel G , et al.. Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy. J Am Soc Nephrol 2002; 13:668A. https://www.researchgate.net/publication/312463048_Eculizumab_C5_complement_inhibitor_in_the_treatment_of_idiopathic_membranous_nephropathy

• PubMed
Appel G , . Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy. J Am Soc Nephrol 2002; 13:668A. https://www.researchgate.net/publication/312463048_Eculizumab_C5_complement_inhibitor_in_the_treatment_of_idiopathic_membranous_nephropathy )| false
• Search Google Scholar
• Export Citation